Strizki JM - Search Results

1

Mapping and characterization of vicriviroc resistance mutations from HIV-1 isolated from treatment-experienced subjects enrolled in a phase II study (VICTOR-E1).

McNicholas PM, Mann PA, Wojcik L, Qiu P, Lee E, McCarthy M, Shen J, Black TA, Strizki JM. McNicholas PM, et al. Among authors: strizki jm. J Acquir Immune Defic Syndr. 2011 Mar 1;56(3):222-9. doi: 10.1097/QAI.0b013e3181ff63ee. J Acquir Immune Defic Syndr. 2011. PMID: 21209592

2

Characterization of emergent HIV resistance in treatment-naive subjects enrolled in a vicriviroc phase 2 trial.

McNicholas P, Wei Y, Whitcomb J, Greaves W, Black TA, Tremblay CL, Strizki JM. McNicholas P, et al. Among authors: strizki jm. J Infect Dis. 2010 May 15;201(10):1470-80. doi: 10.1086/652189. J Infect Dis. 2010. PMID: 20373959 Clinical Trial.

3

Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-Vicriviroc.

McNicholas P, Vilchez RA, Greaves W, Kumar S, Onyebuchi C, Black T, Strizki JM. McNicholas P, et al. Among authors: strizki jm. J Clin Virol. 2012 Oct;55(2):134-9. doi: 10.1016/j.jcv.2012.06.021. Epub 2012 Jul 21. J Clin Virol. 2012. PMID: 22824230

4

Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120.

Ogert RA, Wojcik L, Buontempo C, Ba L, Buontempo P, Ralston R, Strizki J, Howe JA. Ogert RA, et al. Virology. 2008 Apr 10;373(2):387-99. doi: 10.1016/j.virol.2007.12.009. Epub 2008 Jan 10. Virology. 2008. PMID: 18190945 Free article.

5

Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies.

Barnard RJ, Howe JA, Ogert RA, Zeuzem S, Poordad F, Gordon SC, Ralston R, Tong X, Sniukiene V, Strizki J, Ryan D, Long J, Qiu P, Brass CA, Albrecht J, Burroughs M, Vuocolo S, Hazuda DJ. Barnard RJ, et al. Virology. 2013 Sep;444(1-2):329-36. doi: 10.1016/j.virol.2013.06.029. Epub 2013 Jul 19. Virology. 2013. PMID: 23876458 Free article.

6

Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1.

Strizki JM, Tremblay C, Xu S, Wojcik L, Wagner N, Gonsiorek W, Hipkin RW, Chou CC, Pugliese-Sivo C, Xiao Y, Tagat JR, Cox K, Priestley T, Sorota S, Huang W, Hirsch M, Reyes GR, Baroudy BM. Strizki JM, et al. Antimicrob Agents Chemother. 2005 Dec;49(12):4911-9. doi: 10.1128/AAC.49.12.4911-4919.2005. Antimicrob Agents Chemother. 2005. PMID: 16304152 Free PMC article.

7

Quantifying the relationship between HIV-1 susceptibility to CCR5 antagonists and virus affinity for antagonist-occupied co-receptor.

Buontempo PJ, Wojcik L, Buontempo CA, Ogert RA, Strizki JM, Howe JA, Ralston R. Buontempo PJ, et al. Among authors: strizki jm. Virology. 2009 Dec 20;395(2):268-79. doi: 10.1016/j.virol.2009.09.029. Epub 2009 Oct 20. Virology. 2009. PMID: 19846188 Free article.

8

HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use.

Trkola A, Kuhmann SE, Strizki JM, Maxwell E, Ketas T, Morgan T, Pugach P, Xu S, Wojcik L, Tagat J, Palani A, Shapiro S, Clader JW, McCombie S, Reyes GR, Baroudy BM, Moore JP. Trkola A, et al. Among authors: strizki jm. Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):395-400. doi: 10.1073/pnas.012519099. Proc Natl Acad Sci U S A. 2002. PMID: 11782552 Free PMC article.

9

Application of affinity selection-mass spectrometry assays to purification and affinity-based screening of the chemokine receptor CXCR4.

Whitehurst CE, Yao Z, Murphy D, Zhang M, Taremi S, Wojcik L, Strizki JM, Bracken JD, Cheng CC, Yang X, Shipps GW Jr, Ziebell M, Nickbarg E. Whitehurst CE, et al. Among authors: strizki jm. Comb Chem High Throughput Screen. 2012 Jul;15(6):473-85. doi: 10.2174/138620712800563945. Comb Chem High Throughput Screen. 2012. PMID: 22651846

10

A phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients.

Pett SL, McCarthy MC, Cooper DA, MacRae K, Tendolkar A, Norris R, Strizki JM, Williams KM, Emery S. Pett SL, et al. Among authors: strizki jm. Antivir Ther. 2009;14(1):111-5. Antivir Ther. 2009. PMID: 19320244 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

50 results

Search Page

Filters